One of the biggest developments is Casgevy, the first FDA-approved treatment to use CRISPR gene-editing technology. Approved initially for patients aged 12 and older in 2023, Casgevy was expanded in July 2026 to include children as young as 2 with sickle cell disease and recurrent vaso-occlusive crises.
It is an extraordinary development—but it is important to understand what the treatment can and cannot do.
What Makes Sickle Cell Disease So Difficult?
Sickle cell disease is an inherited blood disorder involving hemoglobin, the protein that carries oxygen through the body. A genetic change can cause red blood cells to become rigid and sickle-shaped under certain conditions.
Instead of moving smoothly through tiny blood vessels, these cells can obstruct blood flow. This can result in severe pain episodes, anemia, organ damage and other serious complications. The disease affects around 100,000 people in the United States and disproportionately affects Black Americans.
For many patients, managing the condition means living with the uncertainty of when the next complication might occur.
That is why the arrival of gene therapy has generated so much interest.
How Does CRISPR Treatment Work?
Casgevy does not simply deliver a drug into the bloodstream and wait for it to work.
Instead, doctors collect blood-forming stem cells from the patient’s body. Scientists then use CRISPR/Cas9 gene editing to modify those cells. The goal is to increase production of fetal hemoglobin, or HbF, which can reduce the tendency of red blood cells to sickle.
The edited cells are subsequently returned to the patient’s body after intensive conditioning treatment. They can then establish themselves in the bone marrow and produce blood cells containing higher levels of HbF.
In other words, researchers are not simply treating one symptom. They are attempting to change the behavior of the patient’s blood-forming cells.
Early Results Have Been Encouraging
The results that supported the original FDA approval were particularly striking.
Among 31 evaluable patients who received Casgevy in the pivotal study, 29—about 93.5%—were free from severe vaso-occlusive crises for at least 12 consecutive months during the study’s 24-month evaluation period.
Those numbers help explain why gene editing has become one of the most closely watched developments in modern medicine.
But a successful clinical result does not mean the treatment is simple.
A Breakthrough With a Serious Treatment Journey
Gene therapy is sometimes described as a one-time treatment, but that phrase can make the process sound easier than it really is.
Patients undergoing Casgevy must first have their stem cells collected. They then receive high-dose chemotherapy to prepare the bone marrow before the edited cells are infused.
That conditioning treatment can cause significant side effects, including low blood-cell counts, nausea, mouth sores, infections and other complications. Patients also require specialized medical monitoring during recovery.
There is another important consideration: long-term follow-up is still essential. The FDA requires ongoing monitoring of patients who receive these therapies so researchers can better understand their safety and durability over time.
So while the results are promising, it would be premature to describe gene therapy as a guaranteed permanent cure for everyone with sickle cell disease.
The Bigger Health Issue: Who Can Actually Get It?
Perhaps the most important question surrounding gene therapy is no longer simply “Does it work?”
It is also “Who can access it?”
These treatments require highly specialized hospitals, trained teams, stem-cell collection facilities and intensive medical support. The financial cost is also enormous, creating challenges for healthcare systems and families.
This is particularly important because sickle cell disease disproportionately affects communities that have historically experienced significant healthcare inequalities.
A medical breakthrough has limited public-health value if only a small number of patients can realistically reach it.
What the Future Could Look Like
The story of sickle cell gene therapy is bigger than one treatment.
Researchers are exploring ways to make gene-based treatments safer, easier to administer and more accessible. Future approaches could potentially reduce the need for intensive conditioning or complicated procedures.
At the same time, scientists will need to answer important questions about long-term safety, durability, affordability and access.
The FDA’s July 2026 decision to make Casgevy available to eligible children as young as 2 marks another significant step.
For families affected by sickle cell disease, however, the most meaningful change may be more personal: the possibility of spending less time managing painful complications and more time simply living.
Gene therapy is not the end of the sickle cell story. It may be the beginning of a new chapter—one in which medicine increasingly treats inherited diseases at their biological source rather than only managing their consequences.